CD19 CAR-T细胞治疗原发性中枢神经系统淋巴瘤
该研究报告了正在进行的1期临床试验中5例原发性中枢神经系统淋巴瘤(PCNSL)患者接受CD19 CAR-T细胞治疗的结果。所有患者出现≥1级细胞因子释放综合征和神经毒性,但均 reversible 且可耐受,无治疗相关死亡。初始疗效评估中3/5例(60%,90%CI 19-92%)达完全缓解,另2例疾病稳定,提示该疗法安全可行。
要点
- CD19 CAR-T治疗PCNSL安全可行,毒性可逆且可耐受。
- 5例中3例(60%)达完全缓解,2例疾病稳定。
- 所有患者出现≥1级细胞因子释放综合征和神经毒性,无治疗相关死亡。
核心结论
- CD19 CAR-T细胞治疗原发性中枢神经系统淋巴瘤安全可行,且可诱导完全缓解。
研究设计与样本
- 正在进行的1期临床试验中5例原发性中枢神经系统淋巴瘤患者的亚组分析,试验注册号NCT02153580。
主要发现
- 所有5例患者CAR-T输注后出现≥1级细胞因子释放综合征和神经毒性,毒性可逆且可耐受,无治疗相关死亡。
- 初始疾病反应评估中3/5例(60%;90%置信区间19-92%)影像学显示强化脑病灶消退,达到完全缓解;其余2例疾病稳定。
关键数值与推荐
- 完全缓解定义为强化脑病灶消退,3/5例(60%;90%CI 19-92%)达到。
- 毒性分级:所有患者出现≥1级细胞因子释放综合征和神经毒性,均可逆且可耐受。
临床怎么用
- 对于原发性中枢神经系统淋巴瘤患者,CD19 CAR-T细胞治疗可作为安全可行的治疗选择,但需密切监测细胞因子释放综合征和神经毒性。
局限性
- 研究队列样本量小(n=5),结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-directed chimeric antigen receptor (CD19CAR) T-cell therapy has been successful in treating several B-cell lineage malignancies, including B-cell non-Hodgkin lymphoma (NHL). This modality has not yet been extended to NHL manifesting in the central nervous system (CNS), primarily as a result of concerns for potential toxicity. CD19CAR T cells administered IV are detectable in cerebrospinal fluid (CSF), suggesting that chimeric antigen receptor (CAR) T cells can migrate from the periphery into the CNS, where they can potentially mediate antilymphoma activity. Here, we report the outcome of a subset of patients with primary CNS lymphoma (PCNSL; n = 5) who were treated with CD19CAR T cells in our ongoing phase 1 clinical trial. All patients developed grade ≥ 1 cytokine release syndrome and neurotoxicity post-CAR T-cell infusion; toxicities were reversible and tolerable, and there were no treatment-related deaths. At initial disease response, 3 of 5 patients (60%; 90% confidence interval, 19-92%) seemed to achieve complete remission, as indicated by resolution of enhancing brain lesions; the remaining 2 patients had stable disease. Although the study cohort was small, we demonstrate that using CD19CAR T cells to treat PCNSL can be safe and feasible. This trial was registered at www.clinicaltrials.gov as #NCT02153580.
引用
- Siddiqi T, Wang X, Blanchard MS, et al. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021. PMID: 34492703. doi:10.1182/bloodadvances.2020004106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。